N-Methylamisulpride (developmental code name LB-102) is a dopamine D2 and D3 receptor antagonist and serotonin 5-HT2B and 5-HT7 receptor antagonist which is under development for the treatment of schizophrenia. It is a benzamide derivative and is the N-methylated analogue of amisulpride. The drug is being developed for use both orally and parenterally.